DK1531814T3 - Sustained-release tabletkomposition af pramipexol - Google Patents

Sustained-release tabletkomposition af pramipexol

Info

Publication number
DK1531814T3
DK1531814T3 DK03771807T DK03771807T DK1531814T3 DK 1531814 T3 DK1531814 T3 DK 1531814T3 DK 03771807 T DK03771807 T DK 03771807T DK 03771807 T DK03771807 T DK 03771807T DK 1531814 T3 DK1531814 T3 DK 1531814T3
Authority
DK
Denmark
Prior art keywords
pramipexole
sustained
release tablet
tablet composition
composition
Prior art date
Application number
DK03771807T
Other languages
Danish (da)
English (en)
Inventor
Gregory E Amidon
Loksidh D Ganorkar
John M Heimlich
Ernest J Lee
Robert M Noack
Joseph P Reo
Connie J Skoug
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of DK1531814T3 publication Critical patent/DK1531814T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK03771807T 2002-07-25 2003-07-25 Sustained-release tabletkomposition af pramipexol DK1531814T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39844702P 2002-07-25 2002-07-25
US39842702P 2002-07-25 2002-07-25
US47951303P 2003-06-18 2003-06-18
PCT/US2003/023205 WO2004010997A1 (en) 2002-07-25 2003-07-25 Sustained-release tablet composition of pramipexole

Publications (1)

Publication Number Publication Date
DK1531814T3 true DK1531814T3 (da) 2008-10-13

Family

ID=31192087

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03771807T DK1531814T3 (da) 2002-07-25 2003-07-25 Sustained-release tabletkomposition af pramipexol

Country Status (41)

Country Link
US (2) US20050226926A1 (de)
EP (2) EP1531814B1 (de)
JP (1) JP4700963B2 (de)
KR (1) KR100712832B1 (de)
CN (1) CN1313092C (de)
AP (1) AP2201A (de)
AR (1) AR040681A1 (de)
AT (1) ATE406162T1 (de)
AU (1) AU2003261241B2 (de)
BR (1) BR0312960A (de)
CA (1) CA2492854C (de)
CR (1) CR7661A (de)
CU (1) CU23440B7 (de)
CY (1) CY1110408T1 (de)
DE (1) DE60323235D1 (de)
DK (1) DK1531814T3 (de)
EA (2) EA200702187A1 (de)
EC (1) ECSP055568A (de)
ES (1) ES2310673T3 (de)
GE (1) GEP20074048B (de)
HK (1) HK10777456A1 (de)
HR (1) HRP20041235B1 (de)
IL (1) IL166078A0 (de)
IS (1) IS7623A (de)
MA (1) MA27328A1 (de)
ME (1) MEP52308A (de)
MX (1) MXPA05001054A (de)
MY (1) MY138846A (de)
NO (1) NO334298B1 (de)
NZ (1) NZ537790A (de)
OA (1) OA13303A (de)
PA (1) PA8578301A1 (de)
PE (1) PE20040130A1 (de)
PL (1) PL215587B1 (de)
PT (1) PT1531814E (de)
RS (1) RS51719B (de)
SI (1) SI1531814T1 (de)
TW (1) TWI347849B (de)
UY (1) UY27912A1 (de)
WO (1) WO2004010997A1 (de)
ZA (1) ZA200500439B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
HUP0500001A3 (en) * 2001-12-11 2005-11-28 Univ Virginia Use of pramipexole to treat amyotrophic lateral sclerosis
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
WO2005005484A1 (ja) 2003-07-11 2005-01-20 Asahi Kasei Chemicals Corporation 機能性澱粉粉末
SI1781260T2 (sl) * 2004-08-13 2014-08-29 Boehringer Ingelheim International Gmbh Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol, postopek za izdelavo le-te in njena uporaba
CN101843597A (zh) 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
NZ554360A (en) * 2004-09-09 2009-11-27 Piscofarma S A De C V Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment
EP1731514A1 (de) * 2005-06-02 2006-12-13 Sandoz AG Verfahren zur Herstellung von Pramipexol
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
JP2009537565A (ja) 2006-05-16 2009-10-29 ノップ ニューロサイエンシーズ、インク． Ｒ（＋）およびｓ（−）プラミペキソール組成とそれを利用する方法
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (de) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
EP2150239A1 (de) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Kombination mit einer pramipexol oder ein pharmazeutisch annehmbares salz davon enthaltenden tablettenformulierung mit verlängerter freisetzung
WO2008150741A1 (en) * 2007-06-04 2008-12-11 Drugtech Corporation Controlled release dopamine agonist compositions
CA2725482A1 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
EP2334185A4 (de) 2008-08-19 2011-09-21 Knopp Neurosciences Inc Zusammensetzungen und verfahren zur verwendung von (r)-pramipexol
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
EP2448411A4 (de) * 2009-07-02 2012-11-28 Supernus Pharmaceuticals Inc Verfahren zur behandlung einer neurologischen störung
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations
WO2011086182A2 (en) 2010-01-18 2011-07-21 Synthon Bv Pramipexole extended release tablets
TR201001862A1 (tr) 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
EP2575780A1 (de) 2010-05-24 2013-04-10 Lupin Limited Pramipexolformulierung mit verlängerter freisetzung
KR101307334B1 (ko) 2010-07-02 2013-09-12 주식회사 바이오파마티스 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
JP6329717B2 (ja) 2013-07-12 2018-05-23 ノップ バイオサイエンシーズ エルエルシー 高好酸球値および／または高好塩基球値の治療
EP3033081B1 (de) 2013-08-13 2021-05-12 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von chronischer nesselsucht
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
CN103520128B (zh) 2013-10-12 2018-08-21 石家庄杏林锐步医药科技股份有限公司 一种普拉克索的缓释片剂、制备方法及其用途
EP3609495A4 (de) 2017-04-10 2020-12-02 Chase Therapeutics Corporation Nk1-antagonistenkombination und verfahren zur behandlung von synukleinopathien
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN109316466B (zh) * 2017-07-31 2022-04-05 深圳翰宇药业股份有限公司 一种盐酸普拉克索缓释制剂及其制备方法
CA3072994A1 (en) 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
CN113876729B (zh) * 2021-11-11 2023-05-30 南通联亚药业股份有限公司 一种盐酸普拉克索缓释片剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15735A (en) * 1856-09-16 Improvement in harvesters
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH649215A5 (de) 1981-04-29 1985-05-15 Hoffmann La Roche Pharmazeutische praeparate.
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4709712A (en) 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en) 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
ES2067744T3 (es) 1989-06-09 1995-04-01 Upjohn Co Aminas heterociclicas con actividad sobre el sistema nervioso central.
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
GB9015822D0 (en) 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
EP0998271B3 (de) 1997-06-06 2014-10-29 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
BR9810403A (pt) 1997-07-01 2000-08-29 Pfizer Sais da sertralina e formas de dosagem de liberação sustentada da sertralina
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) * 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
GB9802201D0 (en) * 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
CA2323177A1 (en) 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
DE19906290A1 (de) 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
ATE313319T1 (de) * 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
EA011094B1 (ru) 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
AP2002002410A0 (en) 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
WO2001022820A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2731401A (en) * 1999-12-22 2001-07-03 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
CA2332691C (en) 2000-01-27 2007-11-27 The York Group, Inc. Death care merchandising system
CN1660435A (zh) 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
DE10138275A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
AU2002358270A1 (en) 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CA2488860A1 (en) 2002-07-25 2004-02-05 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004080440A1 (en) 2003-03-11 2004-09-23 Korea United Pharm, Inc. Process for the preparing of hardcapsule formulation containing lansoprazole
BRPI0408999A (pt) 2003-04-04 2006-03-28 Pharmacia Corp comprimidos prensados de multiparticulados de liberação oral prolongada
US20050020589A1 (en) 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
CN101843597A (zh) 2004-08-13 2010-09-29 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
SI1781260T2 (sl) 2004-08-13 2014-08-29 Boehringer Ingelheim International Gmbh Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol, postopek za izdelavo le-te in njena uporaba
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
EP1901720A2 (de) 2005-06-23 2008-03-26 Spherics, Inc. Verbesserte dosierformen zur behandlung von bewegungsstörungen
EP1901721A1 (de) 2005-06-23 2008-03-26 Spherics, Inc. Dosierformen von pramipexol mit verzögerter oder verlängerter-verzögerter freisetzung
JP2009504748A (ja) 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007090881A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2007090883A1 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1886665A1 (de) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastroretentives Freisetzungssystem

Also Published As

Publication number Publication date
KR100712832B1 (ko) 2007-04-30
EP1987832A1 (de) 2008-11-05
HRP20041235B1 (hr) 2013-07-31
JP2005538106A (ja) 2005-12-15
ZA200500439B (en) 2006-08-30
NZ537790A (en) 2005-10-28
US8399016B2 (en) 2013-03-19
EA009663B1 (ru) 2008-02-28
CU23440B7 (es) 2009-10-16
AP2201A (en) 2011-01-24
HRP20041235A2 (en) 2005-06-30
DE60323235D1 (de) 2008-10-09
TW200418523A (en) 2004-10-01
AR040681A1 (es) 2005-04-13
PL375696A1 (en) 2005-12-12
PA8578301A1 (es) 2004-07-20
NO20050093L (no) 2005-02-24
KR20050062516A (ko) 2005-06-23
PE20040130A1 (es) 2004-03-06
TWI347849B (en) 2011-09-01
GEP20074048B (en) 2007-02-26
NO334298B1 (no) 2014-01-27
JP4700963B2 (ja) 2011-06-15
BR0312960A (pt) 2005-06-14
CA2492854A1 (en) 2004-02-05
PL215587B1 (pl) 2013-12-31
ECSP055568A (es) 2005-04-18
UY27912A1 (es) 2004-02-27
US20100316710A1 (en) 2010-12-16
IL166078A0 (en) 2006-01-15
CA2492854C (en) 2009-10-20
EP1531814B1 (de) 2008-08-27
HK10777456A1 (en) 2007-11-30
RS20050059A (en) 2007-08-03
CN1313092C (zh) 2007-05-02
MEP52308A (en) 2011-02-10
EA200500079A1 (ru) 2005-06-30
PT1531814E (pt) 2008-10-29
AU2003261241A1 (en) 2004-02-16
MXPA05001054A (es) 2005-04-08
RS51719B (sr) 2011-10-31
CR7661A (es) 2005-06-08
WO2004010997A1 (en) 2004-02-05
MA27328A1 (fr) 2005-05-02
US20050226926A1 (en) 2005-10-13
WO2004010997A8 (en) 2005-02-24
OA13303A (en) 2007-04-13
MY138846A (en) 2009-07-31
CY1110408T1 (el) 2015-04-29
SI1531814T1 (sl) 2008-12-31
ATE406162T1 (de) 2008-09-15
EA200702187A1 (ru) 2008-06-30
ES2310673T3 (es) 2009-01-16
IS7623A (is) 2004-12-29
EP1531814A1 (de) 2005-05-25
AU2003261241B2 (en) 2009-06-18
CN1671382A (zh) 2005-09-21
AP2005003205A0 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
DK1531814T3 (da) Sustained-release tabletkomposition af pramipexol
CY2015015I1 (el) Παραγωγη τιακουμυκινης
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DK1545475T3 (da) Enterisk sammensætning til fremstillingen af blød kapselvæg
DK2508521T4 (da) Dimaleat af en aminocrotonylforbindelse og fremgangsmåde til fremstilling deraf
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
IS8348A (is) Samrunnin heteróhringasambönd
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
DK1476162T3 (da) Kontrolleret syntese af ziprasidone
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1470732T3 (da) Fremskaffelse af lokaliseringsinformation
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
NO20052655D0 (no) Sammensmeltede heterocykliske forbindelser
IS7585A (is) Ný piperadín efnasambönd
DK1519928T3 (da) Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
ATE444290T1 (de) Oxazolderivate von tetracyclinen
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
IS6633A (is) Samsetningar af fínasteríð töflum
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DK1670773T3 (da) Fremgangsmåde til fremstilling af benzoxazol-sulfonamidforbindelser og mellemprodukter deraf
DK1535612T3 (da) Behandling af hyperurikæmi
ATE340161T1 (de) Herstellung von quinapril hydrochlorid